Japan Tobacco Inc. and D-Wave Announce Collaboration Aimed at Accelerating Innovative Drug Discovery with Quantum AI
2024年10月1日 - 8:00PM
ビジネスワイヤ(英語)
Proof-of-concept project to explore using
quantum computing to revolutionize the speed and quality of
“Quantum AI-driven Drug Discovery,” aimed at creating
first-in-class small molecule pharmaceuticals
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave” or the “Company”), a
leader in quantum computing systems, software, and services and the
world’s first commercial supplier of quantum computers, and the
pharmaceutical division of Japan Tobacco Inc. (“JT”) today
announced plans to collaborate on a joint proof-of-concept project
that will leverage quantum computing technology and artificial
intelligence (“AI”) in the drug discovery process, i.e., “Quantum
AI-driven Drug Discovery.”
Supported by D-Wave's team of professional services experts, the
AI team in JT’s pharmaceutical division will utilize D-Wave's
annealing quantum computing solutions as accelerators in the speed
and quality of training JT’s novel AI-driven analysis systems,
aiming to extend the applicable range of such AI systems in the
drug discovery field (AI-driven Drug Design). The goal of the
project is to pioneer a new process for discovering
'first-in-class' pharmaceutical small compounds.
"In our development of AI-driven drug discovery systems, we have
been focusing on and researching quantum computing technologies as
a speed and quality accelerator in the drug design process,” said
Dr. Masaru Tateno, Chief Scientific Officer (CSO) of JT's
Pharmaceutical Research Center. “In this context, we examine our
novel theory and systems in our joint proof-of-concept project, and
thus we have high expectations for the effectiveness of D-Wave's
annealing quantum computing solutions. By utilizing D-Wave's
quantum technology, we aim to pioneer a new standard that
significantly accelerates the speed and quality of drug discovery
and expands the exploration space for pharmaceutical small
compounds."
"Pharmaceutical companies need to maintain competitiveness while
addressing the challenges of difficulty, uncertainty, and duration
in new drug development, creating an environment that is
accelerating the speed and quality for AI drug discovery,” said Dr.
Alan Baratz, CEO of D-Wave. “D-Wave is committed to supporting JT's
pharmaceutical division in maximizing the capabilities of AI
through quantum computing technology, with the goal of expanding
the exploration space for pharmaceutical small compounds."
Following the proof-of-concept project, JT’s pharmaceutical
division plans to further advance the developed, Quantum AI-driven
Drug Discovery analysis systems and eventually move the application
of quantum computing technology into production operations.
About JT Pharma
JT commenced its pharmaceutical business in 1987 with its
mission to create original and innovative drugs for patients
suffering from diseases around the world. To learn more, visit
https://www.jt.com/about/division/pharma/index.html.
About D-Wave Quantum Inc.
D-Wave is a leader in the development and delivery of quantum
computing systems, software, and services, and is the world’s first
commercial supplier of quantum computers—and the only company
building both annealing quantum computers and gate-model quantum
computers. Our mission is to unlock the power of quantum computing
today to benefit business and society. We do this by delivering
customer value with practical quantum applications for problems as
diverse as logistics, artificial intelligence, materials sciences,
drug discovery, scheduling, cybersecurity, fault detection, and
financial modeling. D-Wave’s technology has been used by some of
the world’s most advanced organizations including Mastercard,
Deloitte, Davidson Technologies, ArcelorMittal, Siemens
Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd.,
DENSO, Lockheed Martin, Forschungszentrum Jülich, University of
Southern California, and Los Alamos National Laboratory.
Forward-Looking Statements
Certain statements in this press release are forward-looking, as
defined in the Private Securities Litigation Reform Act of 1995.
These statements involve risks, uncertainties, and other factors
that may cause actual results to differ materially from the
information expressed or implied by these forward-looking
statements and may not be indicative of future results. These
forward-looking statements are subject to a number of risks and
uncertainties, including, among others, various factors beyond
management’s control, including the risks set forth under the
heading “Risk Factors” discussed under the caption “Item 1A. Risk
Factors” in Part I of our most recent Annual Report on Form 10-K or
any updates discussed under the caption “Item 1A. Risk Factors” in
Part II of our Quarterly Reports on Form 10-Q and in our other
filings with the SEC. Undue reliance should not be placed on the
forward-looking statements in this press release in making an
investment decision, which are based on information available to us
on the date hereof. We undertake no duty to update this information
unless required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241001077960/en/
D-Wave Alex Daigle media@dwavesys.com
D Wave Quantum (NYSE:QBTS)
過去 株価チャート
から 11 2024 まで 12 2024
D Wave Quantum (NYSE:QBTS)
過去 株価チャート
から 12 2023 まで 12 2024